- The stock price of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) increased by over 20% pre-market. This is why it happened.
The stock price of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) increased by over 20% pre-market. Investors are responding to a bullish research report
BTIG analyst Kaveri Pohlma had initiated coverage of Sonnet BioTherapeutics with a “Buy” rating and a $5 price target. The $5 price target represents a 792.86% upside to the current stock price.
In an investor note, Pohlma wrote that Sonnet is an early-stage biotechnology company that is working to develop systemically tolerable cytokines. And Pohlma believes the company has an unusually flexible platform for targeting cytokines and cytokine combinations. Pohlma added that cytokines “could be the next big thing.”
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.
